|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ischemic Stroke | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Stroke | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Cardiovascular Diseases | |||||
| Central Nervous System Diseases | |||||
| Cerebrovascular Disorders | |||||
| Nervous System Diseases | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Pravastatin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Enzyme Inhibitors | |||||
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Translational Research Informatics Center, Kobe, Hyogo, Japan | |||||
| Japanese Ministry of Health, Labor and Welfare | |||||
| Hiroshima University | |||||
| Osaka University | |||||